Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome

Current Medical Research and Opinion

Volumn 22, Issue 7, 2006, Pages 1287-1294

  Widimský, Jiří ^a,c   Sirotiaková, Jana ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Regional Hospital   (Slovakia)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Blood pressure; Glucose metabolism; Hypertension; Isradipine; Lipid profile; Metabolic disorders; Rilmenidine

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; IMIDAZOLINE I1 RECEPTOR; INDAPAMIDE; ISRADIPINE; RILMENIDINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; HYPERTENSION; INSULIN; ISRADIPINE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXAZOLES;

EID: 33746165270     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115577     Document Type: Article

References (47)

1. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia a nd normal glucose tolerance. New Engl J Med 1989;320:702-6
2. Haffner SM, Fong D, Hazuda HP, et al. Hyperinsulinemia, upper body adiposity and cardiovascular risk factors in non-diabetics. Metabolism 1988;37:338-45
3. Rantala AO, Kauma H, Lilja M, et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999;245:163-74
4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-14
5. Rassman J, Gupta S. The metabolic syndrome. Modify root causes, treat risk factors. J Am Acad Phys Assist 2005;18:30-6
6. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
8. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002;288:2709-16
9. Hu G, Qiao Q, Tuomilheto J, et al.; for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76
10. Meigs JB. Epidemiology of the metabolic syndrome, 2002. Am J Managed Care 2002;8:S283-S292
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287:356-9
12. Balkau B, Charles MA for EGIR. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76
13. Ilanne-Parikka P, Eriksson JG, Lindström J, et al. Prevalence of the metabolic syndrome and its components. Diabetes Care 2004;27:2135-40
14. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541-5
15. Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
16. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
17. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304
18. Farmer JA. Hypertension and the metabolic syndrome. Curr Cardiol Reports 2004;6:427-33
19. Irace C, Cortese C, Fiaschi E, et al. Components of the metabolic syndrome and carotid atherosclerosis. Role of elevated blood pressure. Hypertension 2005;45:597-601
20. Cuspidi C, Meani S, Fusi V, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004;22:1991-8
21. Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003;108:3097-101
22. Huggett RJ, Burns J, Mackintosh AF, Mary DASG. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004;44:847-52
23. Sanjuliani AF, Genelhu de Abreu V, Braga JU, Francischetti EA. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J Clin Basic Cardiol 2004;7:19-25
24. Dollery CT, et al. Rilmenidine in mild to moderate essential hypertension. A double-blind, randomized, parallel-group, multicentre comparison with methyldopa in 157 patients. Curr Ther Res 1990;47:194-211
25. Reid JL. Rilmenidine: a clinical overview. Am J Hypertens 2000;13:106S-111S
26. Reid JL. Update on rilmenidine: clinical benefits. Am J Hypertens 2001;14:322S-325S
27. Meredith PA, Reid JL. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study. Am J Cardiovasc Drugs 2004;4:195-200
28. Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000;7:57-61
29. Mpoy M, Vandeleene B, Ketelslegers JM, Lambert A. Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol 1988;61:91D-94D
30. Scemama M, Février B, Beucler I, Dairou F. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. J Cardiovasc Pharmacol 1995;26:S34-S39
31. Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 2005;21:113-9
32. de Luca N, Izzo R, Fontana D, et al Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens 2000;18:1515-22
33. Yildiz G, Sargin M, Sargin H, Yayla A. Effect of rilmenidine, an imidazoline receptor agonist, on clinical, metabolic, and endocrinologic parameters in hypertensives with metabolic syndrome X. Diabet Bilimi 2003;1:71-6
34. McCarty MF. Elevated sympathetic activity may promote insulin resistance syndrome by activating alpha-1 adrenergic receptors on adipocytes. Med Hypotheses 2004;62:830-8
35. Egan BM, Julius S. Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome. Dialogues Cardiovasc Med 2004;9:143-57
36. 1-receptor agonists: do they have a place in the management of hypertension? Am J Cardiovasc Drugs 2001;1:321-6
37. Esler M, Lux A, Jennings G, et al. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. J Hypertens 2004;22:1529-34
38. Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999;34:724-8
39. 1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Drugs Aging 2000;17:133-59
40. Koletsky RJ, Velliquette RA, Ernsberger P. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann NY Acad Sci 2003;1009:251-61
41. Velliquette RA, Ernsberger P. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 2003;306:646-57
42. Gillman MW, Kannel WB, Belanger, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993;125:1148-54
43. Klauser R, Prager R, Gaube S, et al. Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension 1991;17:15-21
44. Gomis R, Vidal J, Novials A, Coves MJ. Effects of isradipine and nifedipine retard in hypertensive patients with type II diabetes mellitus. Am J Hypertens 1993;6:102S-103S
45. Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-tem antihypertensive treatment. J Intern Med 1994;236:37-42
46. Brogden RN, Sorkin EM. Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs 1995;49:618-49
47. Laivuori HM, Laakso M, Tikkanen MJ, et al. Short-term metabolic effects of isradipine and metoprolol in pre-eclampsia. J Hypertens 1999;17:1189-94